We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering speci... Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis. Show more
Kuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, July 2, 2024 NEW YORK, July 2, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder...
CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapyFollow-on dosing with a 55 mg dose of NTLA-2001 led to a 90% median reduction in serum TTR at...
CAMBRIDGE, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.55 | -2.1227325357 | 25.91 | 28.18 | 24.4 | 1669672 | 26.54730408 | CS |
4 | -0.85 | -3.24303700878 | 26.21 | 28.18 | 21.6 | 1692909 | 24.41459249 | CS |
12 | 4.3 | 20.4178537512 | 21.06 | 28.18 | 21.06 | 1640002 | 24.06658996 | CS |
26 | -0.42 | -1.62916989915 | 25.78 | 34.87 | 19.37 | 1571881 | 25.56462729 | CS |
52 | -17.92 | -41.404805915 | 43.28 | 43.56 | 19.37 | 1376209 | 27.78582441 | CS |
156 | -127.24 | -83.3813892529 | 152.6 | 180.5937 | 19.37 | 1172415 | 52.77483284 | CS |
260 | 8.15 | 47.3561882626 | 17.21 | 202.73 | 9.18 | 1150019 | 54.44973616 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions